Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [3]. Core Views - The company plans to acquire land in Beijing for the construction of a research and development platform, which is expected to enhance its innovative capabilities [3]. - The company has demonstrated strong technical capabilities and has achieved significant breakthroughs in the recombinant collagen industry, establishing a leading position in the market [3]. - The company has a robust pipeline of products in clinical trials, with several expected to launch in the next 2-3 years, covering various medical and aesthetic applications [3]. - The establishment of the "Humanized Collagen FAST Database and Product Development Platform" is a strategic move to accelerate original innovation and improve research efficiency [3]. - The company is expected to maintain strong growth, with projected net profits of 700 million, 837 million, and 1.068 billion yuan for the years 2024, 2025, and 2026, respectively [3][4]. Financial Summary - The company reported total revenue of 780 million yuan in 2023, with projections of 1.485 billion yuan in 2024, 1.946 billion yuan in 2025, and 2.520 billion yuan in 2026, reflecting significant growth [4][6]. - The gross profit margin is expected to remain high, with estimates of 92.9% in 2024 and around 92% in subsequent years [4][6]. - The return on equity (ROE) is projected to be 47.8% in 2024, indicating strong profitability relative to shareholder equity [4][6].
锦波生物：拟北京拿地新建研发平台，引领式创新再进一步